Posted by Michael Wonder on 04 Apr 2018
Roche's Alecensa approved in Switzerland
3 April 2018 - Roche said Tuesday that its prescription medicine Alecensa has been approved in Switzerland as a first-line treatment for a type of lung cancer.
The company said the treatment is aimed at patients with advanced or metastatic anaplastic lymphoma kinase-positive, non-small cell lung cancer.
The approval follows the results of the global phase III ALEX study. The study showed that Alecensa significantly reduced the risk of the disease worsening or death by 53% compared with the standard treatment.
